Thirteen new graduate student fellows will pursue exciting new paths of knowledge and discovery.
SMART researchers find the enzyme RlmN, which directly senses chemical and environmental stresses, can be targeted in drug development.
A pilot-scale system, enabled by an $82 million award from the FDA, aims to accelerate the development and production of mRNA technologies.
SMART researchers combine rifaximin and clarithromycin to effectively restore the latter drug's efficacy.
Funding to Daniel Anderson’s lab will advance research on new delivery technology for RNA vaccines and therapies
The global health care company Sanofi is providing $25 million to advance RNA research.
MIT researchers built DiffDock, a model that may one day be able to find new drugs faster than traditional methods and reduce the potential for adverse side effects.
Using these RNA-delivery particles, researchers hope to develop new treatments for cystic fibrosis and other lung diseases.
Developed at SMART, the therapy stimulates the host immune system to more effectively clear bacterial infections and accelerate infected wound healing.